[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"OrthoPediatrics Corp\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":55},{"warningLetters":4,"total":54},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},703,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-19T04:00:00Z\">08\u002F19\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiach-orthopaedics-709827-08192025\">Miach Orthopaedics \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick McBrayer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Miach Orthopaedics \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>69 Milk St Ste 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Westborough\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01581\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pmcbrayer@miachortho.com\"> pmcbrayer@miachortho.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 709827\u003C\u002Fp>\u003Cp>August 19, 2025\u003C\u002Fp>\u003Cp>Dear Mr. McBrayer:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Westborough, MA from March 31, 2025 through April 23, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Bridge-Enhanced ACL Restoration (BEAR) Implant intended for the treatment of anterior cruciate ligament (ACL) injuries. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation Violation(s)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Ms. Rita Paparazzo, Vice President of Quality, Regulatory, and Clinical Affairs, dated May 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audits conducted as a process monitoring activity to ensure that the specified sterility assurance level (SAL) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your firm’s validated E-Beam sterilization process continues to be met for your BEAR Implant devices, is inadequate. The rationale dated 8\u002F2\u002F23 to only use \u003Cstrong>(b)(4)\u003C\u002Fstrong> during sterility testing to recover microorganisms from the BEAR Implant devices and remove the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to detect the presence of anaerobes on the basis that section A.6.1.1 of ISO 11737-1 states “***\u003Cem>If evaluation has shown that testing for anaerobes is not indicated, then this test can be eliminated in the future\u003C\u002Fem>***” and section 6.7 of ISO 11737-2 states “***\u003Cem>Culture conditions shall be selected after consideration of the types of microorganisms expected to be present. The results of this consideration and the rationale for the decisions reached shall be recorded\u003C\u002Fem>***” is unsubstantiated because your historical \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audit data for sterility testing shows that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was unable to detect the presence of a strict anaerobe, \u003Cem>Tissierella Praeacuta\u003C\u002Fem>, which was found to only be present in \u003Cstrong>(b)(4)\u003C\u002Fstrong> during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audit on 10\u002F7\u002F22 (STR-095-006, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Similarly, the results of other \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audits have shown that facultative anaerobes such as \u003Cem>Bacillus licheniformis\u003C\u002Fem> and \u003Cem>Bacillus megaterium\u003C\u002Fem> were only detected in \u003Cstrong>(b)(4)\u003C\u002Fstrong> but not \u003Cstrong>(b)(4)\u003C\u002Fstrong> despite sampling from the same Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Hence, the rationale to eliminate \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterility testing from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audits is not valid due to examples which demonstrate that \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked the sensitivity to detect both strict and\u002For facultative anaerobes on the BEAR Implant devices.\u003C\u002Fp>\u003Cp>Moreover, your decision to only use \u003Cstrong>(b)(4)\u003C\u002Fstrong> conflicts with the recommendation from your microbiologist consultant on 10\u002F26\u002F21 (TR-21-12-10) for “***\u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterility testing of verification dose samples\u003C\u002Fem>***” and section 5.2.2 of STR-095-006 which states \u003Cstrong>(b)(4)\u003C\u002Fstrong> is for recovering aerobes and \u003Cstrong>(b)(4)\u003C\u002Fstrong> is for recovering anaerobes.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-002, the immediate corrections included quarantining and discarding lot numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Starting with Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to re-implement use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for bioburden monitoring of facultative and strict anaerobic microorganisms. In addition, you plan to review bioburden data for 12 months and assess whether use of both media still remains appropriate; establish a new procedure for bioburden monitoring to align with the contract manufacturer’s procedure; revise the process validation procedure to ensure that validated parameters are properly monitored; review all other process validations for the BEAR Implant devices; and revise relevant work instructions as needed to ensure that the validated parameters are properly monitored. However, no timelines were provided for these corrections and\u002For corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to implement sections 1.0 and 4.2 of your “Nonconforming Materials and Processes” procedure (SOP-0017; Rev. B; Effective: 4\u002F12\u002F23) which state “***\u003Cem>products that do not conform to specification requirements are identified, segregated, investigated and dispositioned\u003C\u002Fem>***” and describe the steps for initiation of a nonconformance report, respectively. For example, you did not generate nonconformance reports when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose audit reports for your BEAR Implant devices indicated that Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> exceeded the product requirement specification (PRS) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average) (PRS-001; Rev. F; Effective: 7\u002F10\u002F23 – 12\u002F7\u002F23) at \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average) and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> exceeded the PRS of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average) (PRS-001; Rev. G; Effective: 12\u002F8\u002F23 – 9\u002F18\u002F24) at \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fdevice (average). Moreover, the lack of initiation of nonconformance reports for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> is inconsistent with past actions to initiate NCR 22-002\u002FCAPA 2022-001 (1\u002F17\u002F22) and CAPA 2022-002 (2\u002F28\u002F22) for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> which also exceeded the limits of bioburden.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-001, your immediate corrections are to document decisions and rationale for past production lots (Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) by 5\u002F31\u002F25; establish procedures for bioburden excursions; review a list of process related nonconformances reported to the firm by the contract manufacturer by 5\u002F31\u002F25; and revise the quality agreement with the contract manufacturer (if needed). In addition, you plan to revise the nonconforming product procedure to describe how to evaluate and disposition devices with bioburden excursions and positive tests for sterility by 5\u002F31\u002F25. However, timelines were only provided for some actions and not others. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient and a mechanism for addressing incomplete, ambiguous, or conflicting requirements, as required by 21 CFR 820.30(c).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement the instructions in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) which requires you to consider areas such as performance and intended use, reliability, and safety when identifying user needs and\u002For design input requirements for your resorbable BEAR Implant devices intended to treat anterior cruciate ligament (ACL) injuries. For example, your DCR 2021-011 for the BEAR Implant device lacks user need(s) such as (but not limited to) the need for the implant to achieve full absorption of blood (i.e., hydration) without the use of copious volumes of blood in a timely manner, all while remaining intact.\u003C\u002Fp>\u003Cp>In addition, because the aforementioned user need(s) are absent from the DCR 2021-011 for the BEAR Implant device, you failed to (1) validate that your BEAR Implant device meets these user needs as a part of your design validation under “BEAR Implant Design Validation Protocol” (TP-20-010; Approved 6\u002F17\u002F25) and (2) adequately implement section 4.5.2 of the “Design Control” procedure (SOP-0001; Rev. E; Effective: 7\u002F8\u002F20) which requires translation of “***\u003Cem>user needs into design inputs and assure the design inputs address***intended use and user needs***functional, performance, and safety requirements\u003C\u002Fem>***” and resolution of ambiguous or conflicting requirements prior to approval. For example:\u003C\u002Fp>\u003Cp>a. The design input \"\u003Cem>The BEAR Implant shall be able to absorb whole blood (autologous blood injected during the surgical process)\u003C\u002Fem>\" (9b) in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) is ambiguous because it does not identify parameters (time, volume, technique, etc.) under which the implant must be able to be fully hydrated while remaining intact.\u003C\u002Fp>\u003Cp>Per your instructions for use (IFU) (ML-1002; Rev. H; Effective: 3\u002F2025), the implant “***\u003Cem>is intended to be used with up to 10 ml of autologous blood\u003C\u002Fem>***” and states to “***\u003Cem>hydrate the BEAR Implant with 5-10 mL of non-coagulated autologous blood\u003C\u002Fem>***.” In addition, the “The BEAR® Implant Physeal Sparing Technique” (ML-1274; Rev. A; Effective: 3\u002F2025) describes the technique by which to infuse the implant with blood: “***\u003Cem>Massage the autologous blood into the BEAR Implant, starting with approximately 1mL on the proximal side, then to the sides and finishing with the bottom. Add 1-2mL at a time while massaging the blood in, softening the implant. Once the implant is pliable, inject whole blood into the center of the implant\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>b. The DCR 2021-011 includes design inputs which do not directly address the user need under which they are categorized. For example, the above design input (9b) was inappropriately categorized under the user need (UN-2) of “***\u003Cem>The BEAR Implant must demonstrate non-inferiority in terms of effectiveness when compared with the current standard of care (ACL reconstruction with an autograft) at 2 years post-surgery\u003C\u002Fem>***” and there was no other applicable user need which describes user need(s) of the surgeon such as (but not limited to) the need for the implant to achieve full hydration without the use of copious volumes of blood and absorption of blood in a timely manner, all while remaining intact.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-004, your immediate corrections are to identify a new or existing user need as the basis of the design input “\u003Cstrong>(b)(4)\u003C\u002Fstrong>;” develop a design output specification tied to the new or revised design input; verify that the design output specification meets the design input specification; and develop a test to provide evidence that the new or revised user need is met. Your corrective action is to revise SOP-0001 to require participation of surgeons and other relevant experts in design review for design inputs. However, no timelines were provided for these corrections and\u002For corrective actions. In addition, there were no corrective actions identified to require that surgeons and other experts are included in the development of user needs and to retrospectively review all user needs and design inputs for the BEAR Implant device for any missing user needs, adequacy, and appropriate categorization by user need. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to validate, with a high degree of assurance, that your gelation and lyophilization processes consistently produce BEAR Implant devices which meet the specifications for density (0.062 - 0.072 g\u002Fcm3). For example, although your “Miach BEAR 20510-01 Process Qualification Report” (VAL-08164; Rev. AA; Approved 4\u002F24\u002F24) states that your performance qualification (PQ) demonstrates “***\u003Cem>with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density of the BEAR devices is between \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>***,” this sampling method to use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from \u003Cstrong>(b)(4)\u003C\u002Fstrong> BEAR Implants per lot (Lot #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) does not take into account the impact of an individual implant failing to meet specification, outliers, or standard deviation. Review of the raw data in your PQ revealed that 1 out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the BEAR implants under Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to meet specification (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for density and over \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the density values across lots were at or below the minimum specification, none of which demonstrates a high degree of assurance that your processes result in devices which consistently meet density specifications.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You provided no corrective actions for this deficiency on the basis that an \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an average characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. In addition, confidence intervals based \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plans provide a range within which a value is likely to fall, not a high degree of assurance that a process will produce product that consistently meets specification. Therefore, please provide a response on how you plan to address the above deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, the sampling plan outlined in “7540 Dimensional Inspection” for (FRM-01379; Rev AA) to use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from the first \u003Cstrong>(b)(4)\u003C\u002Fstrong> BEAR Implants per lot to accept lots which meet the density specification (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the premise that the collagen slurry mixture in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing step would have met the homogeneity specification is not based on valid statistical rationale. For example, per your Vice President of Research and Development and Manufacturing, if a single implant fails the density acceptance criteria, it will still be released, so long as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants remain within specification. On the other hand, if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants fails, then density is calculated on every implant within the lot, and all samples that do not meet specification will be treated as a nonconformance and scrapped. However, the rationale for this sampling plan is not based on valid statistical rationale because (1) samples are not taken at random; (2) samples are not based on lot sizes which can be up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> units; (3) individual samples may still fail to meet density specifications, even if the previous collagen slurry specification met the specification for homogeneity; and (4) single implants which do not meet density specifications have the potential to be released if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density specification is met. The practice of releasing product when an individual data point was outside of the specification also constitutes distribution of nonconforming product without valid justification. Your complaint and\u002For corrective and preventive action investigations have determined that the gelation process affects densities such that implants with low densities can cause rapid blood absorption and those with high densities can delay or hinder blood absorption, both of which can render the implant unusable due to disintegration or lack of proper hydration, the result of which is delayed surgery requiring use of a second implant (if available) or impaired \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your hazard analysis (001-003-HZ; Rev. B; Effective: 7\u002F10\u002F23).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Per the response to the process validation observation, which employed the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plan strategy as that used during lot release of product, you provided no corrective actions on the basis that an \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an \u003Cstrong>(b)(4)\u003C\u002Fstrong> characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the \u003Cstrong>(b)(4)\u003C\u002Fstrong> density from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. Therefore, please provide a response as to how you plan to address the above deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and documented evaluation and selection of potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements, as required by 21 CFR 820.50(a)(1).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement:\u003C\u002Fp>\u003Cp>a. Sections 4 and 18 of your “Supplier Quality Agreement” (Approved 1\u002F27\u002F22) which require you to approve protocols and reports for process, sterilization and inspection\u002Ftest validations performed by the contract manufacturer and “***\u003Cem>provide copies of quality records upon request\u003C\u002Fem>***,” respectively. For example, your contract manufacturer refused to provide unredacted supporting documents, such as the process routers, device history records, and process parameters used to manufacture the BEAR Implant device during the FDA inspection.\u003C\u002Fp>\u003Cp>b. Section 4.8 of your “Supplier Management” (SOP-0025; Rev. D; Effective: 12\u002F8\u002F23) which requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> evaluation of major suppliers using the “Supplier Re-evaluation Form” (FRM-0025). For example, your contract manufacturer of the BEAR Implant device has not been evaluated since May 2023 despite being categorized as a major supplier.\u003C\u002Fp>\u003Cp>c. Section 4.1.1 of SOP-0025 which requires “***\u003Cem>no products or services associated with the QMS are to be purchased from a supplier not on the Approved Supplier List\u003C\u002Fem>***.” For example, your firm’s microbiology consultant who authored “Rationale for Eliminating \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Test of Sterility and Anaerobic Bioburden Monitoring” dated 7\u002F30\u002F23 was not on the Approved Supplier List or evaluated. You have been using this consultant since November 2021.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-007, your immediate correction is to complete the 2024 supplier re-evaluation form for the contract manufacturer and for the consultant and revise the quality agreement to allow alternative methods for reviewing all supporting documentation for process, sterilization, and inspection\u002Ftest validations such as onsite review, establishing a master file with the FDA, or having a 3rd party consultant review the documents. As a part of corrective actions, you plan to perform a gap analysis for the approved supplier list and revise SOP-0025 to allow alternative methods for review of supporting documents. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluations to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 4.3.6 of your “Customer Feedback” procedure (SOP-0027; Rev. B – C; Effective: 6\u002F27\u002F24 and 12\u002F8\u002F23) which requires you to categorize customer feedback as complaints, to be processed by the “Complaint Management” procedure (SOP-0019; Rev. C – D; Effective: 12\u002F8\u002F23 and 4\u002F26\u002F24), when they meet the definition of complaints as defined under section 3 of SOP-0027. For example, your customer feedback descriptions in 3 out of 6 reviewed customer feedback forms, which met the definition of complaints, were classified as “Observations” instead of “Complaints” and, therefore, did not include documented evaluations for medical device reporting (MDR) and investigations per sections 4.2 and 4.3 of SOP-0019, respectively, as evidenced below:\u003C\u002Fp>\u003Cp>a. \u003Cu>CF 2024-006 (6\u002F3\u002F24)\u003C\u002Fu>: BEAR Implant “***\u003Cem>hydrating far too quickly (&lt;10 seconds) and becoming unable to properly implant\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>b. \u003Cu>CF 2024-004 (4\u002F12\u002F24)\u003C\u002Fu>: BEAR Implant “***\u003Cem>hydrated EXTREMELY slow. Took 20 cc and maybe 5 min. Much much much slower than average hydration. Could tell the implant was very dense when the surgeon slid Keith needle into it\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>c. \u003Cu>CF 2023-007 (3\u002F7\u002F23)\u003C\u002Fu>: BEAR Implant “***\u003Cem>it was too dense and seemed not to have a porous side. This happened with two of the implants***He is concerned about the variability between implants of the same lot, and does not like the difficulty he had hydrating it\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-009, your immediate corrections are to process the above incidents as complaints and retrospectively review “observations” since 2021 to ensure that no other complaints were missed. As a part of corrective actions, you plan to provide training to ensure that future customer feedback is evaluated in accordance with SOP-0019 and update the training procedure (SOP-004) to control training in accordance with the risk inherent in the process. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>8. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to adequately implement section 4.2 of your firm's “Corrective and Preventive Action Procedure” (SOP-0014; Rev. C; Effective: 9\u002F8\u002F21) which requires completion of a Field Action Decision Form (FADF) and risk assessment if product in the field may be impacted. For example, the FADF for CAPA 2023-001, initiated on 1\u002F27\u002F23 in response to complaints regarding rapid blood absorption and disintegration of BEAR Implants from Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, concluded that a field action was not required per the results of the Health Hazard Evaluation (HHE) Form (DCR 2019-005; Approved 2\u002F17\u002F23) which determined that the hazard of \"ACL is not fully healed\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was “low risk” when an occurrence rating of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was applied. However, this conclusion conflicted with the original “Internal Memorandum***Risk Assessment” conducted per the “Risk Management Plan – BEAR Implant (Project: 001)” (DCR 2020-008; Rev. B; Effective: 8\u002F27\u002F20) on 1\u002F30\u002F23 which found that the risk for this same hazard \u003Cstrong>(b)(4)\u003C\u002Fstrong> was “Unacceptable” (“further risk reduction or additional risk-benefit is required”) when an occurrence rating of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was applied. Applying this same occurrence level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the HHE would have moved the risk level from “low” to “high” (“Field action is required”). Therefore, you failed to conduct an adequate risk assessment under this CAPA 2023-001 in that the discrepancy in occurrence ratings between the HHE and the “Internal Memorandum*** Risk Assessment” was not resolved prior to completion of the FADF.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You stated that there are no BEAR implants that remain in commercial distribution. Under CAPA 2025-006, your immediate correction is to reopen CAPA 2023-001 for review and reiteration if needed. As a corrective action, you plan to revise SOP-0014 to require that FADFs, Health Hazard Assessments, and Risk Assessments are compared for correlation and completeness and that at least two reviewers are included for the assessments. However, no timelines were provided for these corrective actions. In addition, although you obtained Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> from your sales personnel, no corrective actions were identified to document justification for not reporting a correction and\u002For removal of product from the field, including removals limited to sales personnel, to the FDA. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>9. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fp>\u003Cp>Specifically, during the inspection, your firm presented its MDR procedure titled “Medical Device Reporting,” SOP‐0023, Revision B, dated: 8‐Dec‐2023. For example, after reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>a. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\u003Cp>i. The procedure SOP‐0023, Revision B, does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\u003Cp>ii. There are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” and “serious injury,” nor the definition of “reasonably suggests” found in 21 CFR 803.20(c)(1). The absence of these definitions may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a). Without adequate definitions, your procedure lacks executable instructions or the level of detail needed to ensure timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements.\u003C\u002Fp>\u003Cp>b. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003C\u002Fp>\u003Cp>c. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include the circumstances under which your firm must submit initial 30-day, supplement or follow-up and 5‐day reports and the requirements for such reports.\u003C\u002Fp>\u003Cp>d. The procedure SOP‐0023, Revision B, does not adequately describe how your firm will address documentation and record‐keeping requirements, as required by 21 CFR 803.17(b). Specifically, while Section 4.1.3 of the SOP references retaining data for reportable events, it lacks sufficient detail on how the deliberations and decision-making processes used to determine whether an event is reportable or not is to be documented, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\u003Cp>Your firm’s response dated May 13, 2025 did not address the noted procedural deficiencies as they were not listed on the FDA Form 483.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s BEAR implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>10. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example, the information included for Complaint 2023‐011 reasonably suggests that the patient developed an infection at the site of BEAR implant after falling 4.5 weeks post-surgery. Although the information included for the complaint establishes that the device did not malfunction in that the ACL damage observed was the result of a re‐tear due to the fall, the occurrence of the infection in the area surrounding the implantation reasonably suggests that the device may have been a factor in the serious injury event that necessitated irrigation and antibiotic treatment to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on August 23, 2023; however, no corresponding MDR was received by the FDA.\u003C\u002Fp>\u003Cp>Your firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. However, the response indicated that your firm conducted a reportability evaluation in relation to Observation 9. Upon review, the response did not include any information regarding plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\u003C\u002Fp>\u003Cp>\u003Cstrong>11. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example, the information included for Complaints 2022‐001, 2023‐004 and 2024‐001 reasonably suggests that your firm’s BEAR implant malfunctioned (i.e., improper hydration) while in use. The device is a long‐term implantable device. Generally, malfunctions are reportable if they involve a long-term implant and are likely to cause or contribute to death or serious injury, or the malfunction results in the failure of the device to perform its essential function, thereby compromising its therapeutic effectiveness which could cause or contribute to a death or serious injury. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63858 (Dec. 11, 1995), Comment 12, for more information. We believe an improperly hydrated BEAR implant could compromise its structural integrity and therapeutic function, leading to serious complications that might cause or contribute to a death or serious injury. Therefore, the referenced complaints represent MDR reportable events as defined in 21 CFR 803.3. Your firm became aware of information on September 1, 2022, for Complaint 2022‐001, on February 24, 2023, for Complaint 2023‐004, and on January 11, 2024, for Complaint 2024‐001. However, the FDA has not received an MDR for any of these referenced events.\u003C\u002Fp>\u003Cp>Your firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. The response noted that your firm conducted a reportability evaluation and will submit MDRs for Complaints 2022‐001 and 2024‐001. However, the response does not address Complaint 2023‐004. Additionally, your firm has not provided any information indicating plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 709827” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Rita Paparazzo\u003Cbr>VP of Quality, Regulatory, and Clinical Affairs\u003Cbr>rpaparazzo@miachortho.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick McBrayer\n\nRecipient Title\n\nPresident & CEO\n\nMiach Orthopaedics\n\n69 Milk St Ste 100\n\nWestborough, MA 01581\n\nUnited States\n\npmcbrayer@miachortho.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 709827\nAugust 19, 2025\nDear Mr. McBrayer:\nDuring an inspection of your firm located in Westborough, MA from March 31, 2025 through April 23, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Bridge-Enhanced ACL Restoration (BEAR) Implant intended for the treatment of anterior cruciate ligament (ACL) injuries. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Ms. Rita Paparazzo, Vice President of Quality, Regulatory, and Clinical Affairs, dated May 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\n1. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\nSpecifically, the (b)(4) dose audits conducted as a process monitoring activity to ensure that the specified sterility assurance level (SAL) of (b)(4) of your firm’s validated E-Beam sterilization process continues to be met for your BEAR Implant devices, is inadequate. The rationale dated 8\u002F2\u002F23 to only use (b)(4) during sterility testing to recover microorganisms from the BEAR Implant devices and remove the use of (b)(4) to detect the presence of anaerobes on the basis that section A.6.1.1 of ISO 11737-1 states “***If evaluation has shown that testing for anaerobes is not indicated, then this test can be eliminated in the future***” and section 6.7 of ISO 11737-2 states “***Culture conditions shall be selected after consideration of the types of microorganisms expected to be present. The results of this consideration and the rationale for the decisions reached shall be recorded***” is unsubstantiated because your historical (b)(4) dose audit data for sterility testing shows that (b)(4) was unable to detect the presence of a strict anaerobe, Tissierella Praeacuta, which was found to only be present in (b)(4) during a (b)(4) dose audit on 10\u002F7\u002F22 (STR-095-006, Lot # (b)(4)). Similarly, the results of other (b)(4) dose audits have shown that facultative anaerobes such as Bacillus licheniformis and Bacillus megaterium were only detected in (b)(4) but not (b)(4) despite sampling from the same Lot # (b)(4) and Lot # (b)(4). Hence, the rationale to eliminate (b)(4) for sterility testing from the (b)(4) dose audits is not valid due to examples which demonstrate that (b)(4) lacked the sensitivity to detect both strict and\u002For facultative anaerobes on the BEAR Implant devices.\nMoreover, your decision to only use (b)(4) conflicts with the recommendation from your microbiologist consultant on 10\u002F26\u002F21 (TR-21-12-10) for “***(b)(4) for sterility testing of verification dose samples***” and section 5.2.2 of STR-095-006 which states (b)(4) is for recovering aerobes and (b)(4) is for recovering anaerobes.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-002, the immediate corrections included quarantining and discarding lot numbers (b)(4) through (b)(4). Starting with Lot # (b)(4), you plan to re-implement use of (b)(4) for bioburden monitoring of facultative and strict anaerobic microorganisms. In addition, you plan to review bioburden data for 12 months and assess whether use of both media still remains appropriate; establish a new procedure for bioburden monitoring to align with the contract manufacturer’s procedure; revise the process validation procedure to ensure that validated parameters are properly monitored; review all other process validations for the BEAR Implant devices; and revise relevant work instructions as needed to ensure that the validated parameters are properly monitored. However, no timelines were provided for these corrections and\u002For corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nYou failed to implement sections 1.0 and 4.2 of your “Nonconforming Materials and Processes” procedure (SOP-0017; Rev. B; Effective: 4\u002F12\u002F23) which state “***products that do not conform to specification requirements are identified, segregated, investigated and dispositioned***” and describe the steps for initiation of a nonconformance report, respectively. For example, you did not generate nonconformance reports when the (b)(4) dose audit reports for your BEAR Implant devices indicated that Lot # (b)(4) exceeded the product requirement specification (PRS) of (b)(4) CFU\u002Fdevice (average) (PRS-001; Rev. F; Effective: 7\u002F10\u002F23 – 12\u002F7\u002F23) at (b)(4) CFU\u002Fdevice (average) and Lot # (b)(4) exceeded the PRS of (b)(4) CFU\u002Fdevice (average) (PRS-001; Rev. G; Effective: 12\u002F8\u002F23 – 9\u002F18\u002F24) at (b)(4) CFU\u002Fdevice (average). Moreover, the lack of initiation of nonconformance reports for Lot # (b)(4) and Lot # (b)(4) is inconsistent with past actions to initiate NCR 22-002\u002FCAPA 2022-001 (1\u002F17\u002F22) and CAPA 2022-002 (2\u002F28\u002F22) for Lot # (b)(4) and Lot # (b)(4) which also exceeded the limits of bioburden.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-001, your immediate corrections are to document decisions and rationale for past production lots (Lot # (b)(4) and (b)(4)) by 5\u002F31\u002F25; establish procedures for bioburden excursions; review a list of process related nonconformances reported to the firm by the contract manufacturer by 5\u002F31\u002F25; and revise the quality agreement with the contract manufacturer (if needed). In addition, you plan to revise the nonconforming product procedure to describe how to evaluate and disposition devices with bioburden excursions and positive tests for sterility by 5\u002F31\u002F25. However, timelines were only provided for some actions and not others. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient and a mechanism for addressing incomplete, ambiguous, or conflicting requirements, as required by 21 CFR 820.30(c).\nSpecifically, you failed to implement the instructions in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) which requires you to consider areas such as performance and intended use, reliability, and safety when identifying user needs and\u002For design input requirements for your resorbable BEAR Implant devices intended to treat anterior cruciate ligament (ACL) injuries. For example, your DCR 2021-011 for the BEAR Implant device lacks user need(s) such as (but not limited to) the need for the implant to achieve full absorption of blood (i.e., hydration) without the use of copious volumes of blood in a timely manner, all while remaining intact.\nIn addition, because the aforementioned user need(s) are absent from the DCR 2021-011 for the BEAR Implant device, you failed to (1) validate that your BEAR Implant device meets these user needs as a part of your design validation under “BEAR Implant Design Validation Protocol” (TP-20-010; Approved 6\u002F17\u002F25) and (2) adequately implement section 4.5.2 of the “Design Control” procedure (SOP-0001; Rev. E; Effective: 7\u002F8\u002F20) which requires translation of “***user needs into design inputs and assure the design inputs address***intended use and user needs***functional, performance, and safety requirements***” and resolution of ambiguous or conflicting requirements prior to approval. For example:\na. The design input \"The BEAR Implant shall be able to absorb whole blood (autologous blood injected during the surgical process)\" (9b) in the “BEAR® Scaffold Design Requirements Trace Matrix” (DCR 2021-011; Rev. D; Effective: 10\u002F1\u002F21) is ambiguous because it does not identify parameters (time, volume, technique, etc.) under which the implant must be able to be fully hydrated while remaining intact.\nPer your instructions for use (IFU) (ML-1002; Rev. H; Effective: 3\u002F2025), the implant “***is intended to be used with up to 10 ml of autologous blood***” and states to “***hydrate the BEAR Implant with 5-10 mL of non-coagulated autologous blood***.” In addition, the “The BEAR® Implant Physeal Sparing Technique” (ML-1274; Rev. A; Effective: 3\u002F2025) describes the technique by which to infuse the implant with blood: “***Massage the autologous blood into the BEAR Implant, starting with approximately 1mL on the proximal side, then to the sides and finishing with the bottom. Add 1-2mL at a time while massaging the blood in, softening the implant. Once the implant is pliable, inject whole blood into the center of the implant***.”\nb. The DCR 2021-011 includes design inputs which do not directly address the user need under which they are categorized. For example, the above design input (9b) was inappropriately categorized under the user need (UN-2) of “***The BEAR Implant must demonstrate non-inferiority in terms of effectiveness when compared with the current standard of care (ACL reconstruction with an autograft) at 2 years post-surgery***” and there was no other applicable user need which describes user need(s) of the surgeon such as (but not limited to) the need for the implant to achieve full hydration without the use of copious volumes of blood and absorption of blood in a timely manner, all while remaining intact.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-004, your immediate corrections are to identify a new or existing user need as the basis of the design input “(b)(4);” develop a design output specification tied to the new or revised design input; verify that the design output specification meets the design input specification; and develop a test to provide evidence that the new or revised user need is met. Your corrective action is to revise SOP-0001 to require participation of surgeons and other relevant experts in design review for design inputs. However, no timelines were provided for these corrections and\u002For corrective actions. In addition, there were no corrective actions identified to require that surgeons and other experts are included in the development of user needs and to retrospectively review all user needs and design inputs for the BEAR Implant device for any missing user needs, adequacy, and appropriate categorization by user need. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you failed to validate, with a high degree of assurance, that your gelation and lyophilization processes consistently produce BEAR Implant devices which meet the specifications for density (0.062 - 0.072 g\u002Fcm3). For example, although your “Miach BEAR 20510-01 Process Qualification Report” (VAL-08164; Rev. AA; Approved 4\u002F24\u002F24) states that your performance qualification (PQ) demonstrates “***with (b)(4), the (b)(4) density of the BEAR devices is between (b)(4)***,” this sampling method to use the (b)(4) density from (b)(4) BEAR Implants per lot (Lot #: (b)(4); and (b)(4)) does not take into account the impact of an individual implant failing to meet specification, outliers, or standard deviation. Review of the raw data in your PQ revealed that 1 out of (b)(4) of the BEAR implants under Lot # (b)(4) failed to meet specification ((b)(4)) for density and over (b)(4) of the density values across lots were at or below the minimum specification, none of which demonstrates a high degree of assurance that your processes result in devices which consistently meet density specifications.\nWe reviewed your firm’s response and conclude that it is not adequate. You provided no corrective actions for this deficiency on the basis that an (b)(4) sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an average characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the (b)(4) density from the (b)(4) lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. In addition, confidence intervals based (b)(4) sampling plans provide a range within which a value is likely to fall, not a high degree of assurance that a process will produce product that consistently meets specification. Therefore, please provide a response on how you plan to address the above deficiency.\n5. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\nSpecifically, the sampling plan outlined in “7540 Dimensional Inspection” for (FRM-01379; Rev AA) to use the (b)(4) density from the first (b)(4) BEAR Implants per lot to accept lots which meet the density specification ((b)(4)) on the premise that the collagen slurry mixture in the (b)(4) manufacturing step would have met the homogeneity specification is not based on valid statistical rationale. For example, per your Vice President of Research and Development and Manufacturing, if a single implant fails the density acceptance criteria, it will still be released, so long as the (b)(4) density of the (b)(4) implants remain within specification. On the other hand, if the (b)(4) density of the (b)(4) implants fails, then density is calculated on every implant within the lot, and all samples that do not meet specification will be treated as a nonconformance and scrapped. However, the rationale for this sampling plan is not based on valid statistical rationale because (1) samples are not taken at random; (2) samples are not based on lot sizes which can be up to (b)(4) units; (3) individual samples may still fail to meet density specifications, even if the previous collagen slurry specification met the specification for homogeneity; and (4) single implants which do not meet density specifications have the potential to be released if the (b)(4) density specification is met. The practice of releasing product when an individual data point was outside of the specification also constitutes distribution of nonconforming product without valid justification. Your complaint and\u002For corrective and preventive action investigations have determined that the gelation process affects densities such that implants with low densities can cause rapid blood absorption and those with high densities can delay or hinder blood absorption, both of which can render the implant unusable due to disintegration or lack of proper hydration, the result of which is delayed surgery requiring use of a second implant (if available) or impaired (b)(4) per lines (b)(4) through (b)(4) of your hazard analysis (001-003-HZ; Rev. B; Effective: 7\u002F10\u002F23).\nWe reviewed your firm’s response and conclude that it is not adequate. Per the response to the process validation observation, which employed the same (b)(4) sampling plan strategy as that used during lot release of product, you provided no corrective actions on the basis that an (b)(4) sampling plan is an acceptable means of showing that a process is able to consistently meet specification because it offers statistical confidence that an (b)(4) characteristic is repeatable and reliable. In addition, you state this approach was used during process validation because the (b)(4) density from the (b)(4) lots was also used during clinical trials. However, this rationale does not take into account the impact of an individual implant failing to meet specification or high standard deviations. Therefore, please provide a response as to how you plan to address the above deficiency.\n6. Failure to establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and documented evaluation and selection of potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements, as required by 21 CFR 820.50(a)(1).\nSpecifically, you failed to implement:\na. Sections 4 and 18 of your “Supplier Quality Agreement” (Approved 1\u002F27\u002F22) which require you to approve protocols and reports for process, sterilization and inspection\u002Ftest validations performed by the contract manufacturer and “***provide copies of quality records upon request***,” respectively. For example, your contract manufacturer refused to provide unredacted supporting documents, such as the process routers, device history records, and process parameters used to manufacture the BEAR Implant device during the FDA inspection.\nb. Section 4.8 of your “Supplier Management” (SOP-0025; Rev. D; Effective: 12\u002F8\u002F23) which requires (b)(4) evaluation of major suppliers using the “Supplier Re-evaluation Form” (FRM-0025). For example, your contract manufacturer of the BEAR Implant device has not been evaluated since May 2023 despite being categorized as a major supplier.\nc. Section 4.1.1 of SOP-0025 which requires “***no products or services associated with the QMS are to be purchased from a supplier not on the Approved Supplier List***.” For example, your firm’s microbiology consultant who authored “Rationale for Eliminating (b)(4) for the Test of Sterility and Anaerobic Bioburden Monitoring” dated 7\u002F30\u002F23 was not on the Approved Supplier List or evaluated. You have been using this consultant since November 2021.\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-007, your immediate correction is to complete the 2024 supplier re-evaluation form for the contract manufacturer and for the consultant and revise the quality agreement to allow alternative methods for reviewing all supporting documentation for process, sterilization, and inspection\u002Ftest validations such as onsite review, establishing a master file with the FDA, or having a 3rd party consultant review the documents. As a part of corrective actions, you plan to perform a gap analysis for the approved supplier list and revise SOP-0025 to allow alternative methods for review of supporting documents. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n7. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluations to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).\nSpecifically, you failed to implement section 4.3.6 of your “Customer Feedback” procedure (SOP-0027; Rev. B – C; Effective: 6\u002F27\u002F24 and 12\u002F8\u002F23) which requires you to categorize customer feedback as complaints, to be processed by the “Complaint Management” procedure (SOP-0019; Rev. C – D; Effective: 12\u002F8\u002F23 and 4\u002F26\u002F24), when they meet the definition of complaints as defined under section 3 of SOP-0027. For example, your customer feedback descriptions in 3 out of 6 reviewed customer feedback forms, which met the definition of complaints, were classified as “Observations” instead of “Complaints” and, therefore, did not include documented evaluations for medical device reporting (MDR) and investigations per sections 4.2 and 4.3 of SOP-0019, respectively, as evidenced below:\na. CF 2024-006 (6\u002F3\u002F24): BEAR Implant “***hydrating far too quickly (\u003C10 seconds) and becoming unable to properly implant***.”\nb. CF 2024-004 (4\u002F12\u002F24): BEAR Implant “***hydrated EXTREMELY slow. Took 20 cc and maybe 5 min. Much much much slower than average hydration. Could tell the implant was very dense when the surgeon slid Keith needle into it***.”\nc. CF 2023-007 (3\u002F7\u002F23): BEAR Implant “***it was too dense and seemed not to have a porous side. This happened with two of the implants***He is concerned about the variability between implants of the same lot, and does not like the difficulty he had hydrating it***.”\nWe reviewed your firm’s response and conclude that it is not adequate. Under CAPA 2025-009, your immediate corrections are to process the above incidents as complaints and retrospectively review “observations” since 2021 to ensure that no other complaints were missed. As a part of corrective actions, you plan to provide training to ensure that future customer feedback is evaluated in accordance with SOP-0019 and update the training procedure (SOP-004) to control training in accordance with the risk inherent in the process. However, no timelines were provided for these corrective actions. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n8. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, you failed to adequately implement section 4.2 of your firm's “Corrective and Preventive Action Procedure” (SOP-0014; Rev. C; Effective: 9\u002F8\u002F21) which requires completion of a Field Action Decision Form (FADF) and risk assessment if product in the field may be impacted. For example, the FADF for CAPA 2023-001, initiated on 1\u002F27\u002F23 in response to complaints regarding rapid blood absorption and disintegration of BEAR Implants from Lot # (b)(4), concluded that a field action was not required per the results of the Health Hazard Evaluation (HHE) Form (DCR 2019-005; Approved 2\u002F17\u002F23) which determined that the hazard of \"ACL is not fully healed\" ((b)(4)) was “low risk” when an occurrence rating of (b)(4) was applied. However, this conclusion conflicted with the original “Internal Memorandum***Risk Assessment” conducted per the “Risk Management Plan – BEAR Implant (Project: 001)” (DCR 2020-008; Rev. B; Effective: 8\u002F27\u002F20) on 1\u002F30\u002F23 which found that the risk for this same hazard (b)(4) was “Unacceptable” (“further risk reduction or additional risk-benefit is required”) when an occurrence rating of (b)(4) was applied. Applying this same occurrence level of (b)(4) to the HHE would have moved the risk level from “low” to “high” (“Field action is required”). Therefore, you failed to conduct an adequate risk assessment under this CAPA 2023-001 in that the discrepancy in occurrence ratings between the HHE and the “Internal Memorandum*** Risk Assessment” was not resolved prior to completion of the FADF.\nWe reviewed your firm’s response and conclude that it is not adequate. You stated that there are no BEAR implants that remain in commercial distribution. Under CAPA 2025-006, your immediate correction is to reopen CAPA 2023-001 for review and reiteration if needed. As a corrective action, you plan to revise SOP-0014 to require that FADFs, Health Hazard Assessments, and Risk Assessments are compared for correlation and completeness and that at least two reviewers are included for the assessments. However, no timelines were provided for these corrective actions. In addition, although you obtained Lot #(b)(4) from your sales personnel, no corrective actions were identified to document justification for not reporting a correction and\u002For removal of product from the field, including removals limited to sales personnel, to the FDA. Therefore, please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nMedical Device Reporting (MDR) Violation(s)\n9. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nSpecifically, during the inspection, your firm presented its MDR procedure titled “Medical Device Reporting,” SOP‐0023, Revision B, dated: 8‐Dec‐2023. For example, after reviewing the procedure, the following deficiencies were noted:\na. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\ni. The procedure SOP‐0023, Revision B, does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\nii. There are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” and “serious injury,” nor the definition of “reasonably suggests” found in 21 CFR 803.20(c)(1). The absence of these definitions may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a). Without adequate definitions, your procedure lacks executable instructions or the level of detail needed to ensure timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements.\nb. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\nc. The procedure SOP‐0023, Revision B, does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include the circumstances under which your firm must submit initial 30-day, supplement or follow-up and 5‐day reports and the requirements for such reports.\nd. The procedure SOP‐0023, Revision B, does not adequately describe how your firm will address documentation and record‐keeping requirements, as required by 21 CFR 803.17(b). Specifically, while Section 4.1.3 of the SOP references retaining data for reportable events, it lacks sufficient detail on how the deliberations and decision-making processes used to determine whether an event is reportable or not is to be documented, as required under 21 CFR 803.18(b)(1)(i).\nYour firm’s response dated May 13, 2025 did not address the noted procedural deficiencies as they were not listed on the FDA Form 483.\nOur inspection also revealed that your firm’s BEAR implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\n10. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint 2023‐011 reasonably suggests that the patient developed an infection at the site of BEAR implant after falling 4.5 weeks post-surgery. Although the information included for the complaint establishes that the device did not malfunction in that the ACL damage observed was the result of a re‐tear due to the fall, the occurrence of the infection in the area surrounding the implantation reasonably suggests that the device may have been a factor in the serious injury event that necessitated irrigation and antibiotic treatment to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on August 23, 2023; however, no corresponding MDR was received by the FDA.\nYour firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. However, the response indicated that your firm conducted a reportability evaluation in relation to Observation 9. Upon review, the response did not include any information regarding plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\n11. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Complaints 2022‐001, 2023‐004 and 2024‐001 reasonably suggests that your firm’s BEAR implant malfunctioned (i.e., improper hydration) while in use. The device is a long‐term implantable device. Generally, malfunctions are reportable if they involve a long-term implant and are likely to cause or contribute to death or serious injury, or the malfunction results in the failure of the device to perform its essential function, thereby compromising its therapeutic effectiveness which could cause or contribute to a death or serious injury. See Medical Devices; Medical User Facility and Manufacturing Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63858 (Dec. 11, 1995), Comment 12, for more information. We believe an improperly hydrated BEAR implant could compromise its structural integrity and therapeutic function, leading to serious complications that might cause or contribute to a death or serious injury. Therefore, the referenced complaints represent MDR reportable events as defined in 21 CFR 803.3. Your firm became aware of information on September 1, 2022, for Complaint 2022‐001, on February 24, 2023, for Complaint 2023‐004, and on January 11, 2024, for Complaint 2024‐001. However, the FDA has not received an MDR for any of these referenced events.\nYour firm’s response dated May 13, 2025, did not address this violation, as it was not listed on the FDA Form 483. The response noted that your firm conducted a reportability evaluation and will submit MDRs for Complaints 2022‐001 and 2024‐001. However, the response does not address Complaint 2023‐004. Additionally, your firm has not provided any information indicating plans to implement systemic corrective actions, such as conducting a retrospective review of previously received complaints to assess MDR reportability.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 709827” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nRita Paparazzo\nVP of Quality, Regulatory, and Clinical Affairs\nrpaparazzo@miachortho.com","Miach Orthopaedics","miach-orthopaedics-709827-08192025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiach-orthopaedics-709827-08192025","2026-10-26T08:09:24.573281+00:00","Warning Letter","Issued","2025-08-26","709827","Medical Devices","Patrick McBrayer","2026-08-19T16:29:01.377+00:00","VIA Electronic Mail","2025-08-19",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":37,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},2143,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-03-28T13:20:00Z\">03\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-14T04:00:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023\">Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Bioresearch Monitoring Program\u002FIRB ","Bioresearch Monitoring Program\u002FIRB","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert J. Hayashi, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>660 South Euclid Avenue, Box 8116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63110-1010\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref.: 23-HFD-45-03-02\u003Cbr>\n\u003Cbr>\nDear Dr. Hayashi:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>, of investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>requires that you omit certain \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatments for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the investigational plan for Protocol&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\u003C\u002Fp>\n\n\u003Cp>1. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires that you omit administration of Day 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the final 2 cycles of maintenance therapy for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> was a pediatric subject (5 years old) randomized to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, this subject was administered 12 mg of \u003Cstrong>(b)(4)\u003C\u002Fstrong> on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on \u003Cstrong>(b)(6)\u003C\u002Fstrong>, respectively. As a result, this subject underwent invasive procedures associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered \u003Cstrong>(b)(4)\u003C\u002Fstrong> are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an increased risk of infection associated with lumbar punctures.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\u003C\u002Fp>\n\n\u003Cp>You also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> from Day 1 of Cycles 5 and 6 for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reinforcing the need to calculate the end of therapy and when the last administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for \u003Cstrong>(b)(6)&nbsp;\u003C\u002Fstrong>ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong> administration, and that training on these SOPs was provided.\u003C\u002Fp>\n\n\u003Cp>2. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires an \u003Cstrong>(b)(4)\u003C\u002Fstrong> before the initiation of any cycle of 3-day interval of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)\u003C\u002Fstrong>) administration. If this treatment eligibility criterion is not met, the 3-day course of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) is not initiated. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> had a calculated \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(6)\u003C\u002Fstrong>; however, this subject received a 3-day course of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on Days 1 to 3 of Cycle 3 (\u003Cstrong>(b)(6)\u003C\u002Fstrong>). Thus, you failed to ensure that the only enrolled subject in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong>, met the required treatment eligibility criterion before the administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\u003C\u002Fp>\n\n\u003Cp>As described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\u003C\u002Fp>\n\n\u003Cp>Additionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational \u003Cstrong>(b)(6)\u003C\u002Fstrong> agent; (2) the creation of procedural SOPs for \u003Cstrong>(b)(6)\u003C\u002Fstrong> ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong>, with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (4) good clinical practice training.\u003C\u002Fp>\n\n\u003Cp>We acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\u003C\u002Fp>\n\n\u003Cp>We emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n03\u002F14\u002F2023 07:42:17 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert J. Hayashi, M.D.\n\nRobert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\n\n660 South Euclid Avenue, Box 8116\n\nSaint Louis, MO 63110-1010\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRef.: 23-HFD-45-03-02\n\nDear Dr. Hayashi:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\n\nProtocol (b)(4), “(b)(4),” of the investigational drug (b)(4), performed for the (b)(4)\n\nProtocol (b)(4), “(b)(4), of investigational drug (b)(4) performed for the (b)(4)\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\n\nYou failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\n\nAs a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol (b)(4) requires that you omit certain (b)(4) treatments for subjects randomized into the (b)(4). In addition, the investigational plan for Protocol (b)(4) requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\n\n1. The investigational plan for Protocol (b)(4) requires that you omit administration of Day 1 (b)(4) during the final 2 cycles of maintenance therapy for subjects randomized into the (b)(4). Subject (b)(6) was a pediatric subject (5 years old) randomized to the (b)(4); however, this subject was administered 12 mg of (b)(4) on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on (b)(6), respectively. As a result, this subject underwent invasive procedures associated with (b)(4) administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered (b)(4) are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with (b)(4), and an increased risk of infection associated with lumbar punctures.\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of (b)(4) and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\n\nYou also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove (b)(4) from Day 1 of Cycles 5 and 6 for (b)(4), in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive (b)(4).\n\nFurthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol (b)(4), reinforcing the need to calculate the end of therapy and when the last administration of (b)(4) is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for (b)(6) ordering, to minimize errors in (b)(6) administration, and that training on these SOPs was provided.\n\n2. The investigational plan for Protocol (b)(4) requires an (b)(4) before the initiation of any cycle of 3-day interval of (b)(4) ((b)(4)) administration. If this treatment eligibility criterion is not met, the 3-day course of (b)(4) ((b)(4)) is not initiated. Subject (b)(6) had a calculated (b)(4) on (b)(6); however, this subject received a 3-day course of (b)(4) ((b)(4)) on Days 1 to 3 of Cycle 3 ((b)(6)). Thus, you failed to ensure that the only enrolled subject in Protocol (b)(4), Subject (b)(6), met the required treatment eligibility criterion before the administration of (b)(4).\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an (b)(4) for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\n\nAs described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\n\nAdditionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational (b)(6) agent; (2) the creation of procedural SOPs for (b)(6) ordering, to minimize errors in (b)(6), with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of (b)(4); and (4) good clinical practice training.\n\nWe acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\n\nWe emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\n\nFailure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n03\u002F14\u002F2023 07:42:17 AM","Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics","robert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","2026-10-26T08:09:50.433203+00:00","2023-03-28","654873","Drugs","Robert J. Hayashi, M.D.","2026-08-20T01:10:40.684+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2023-03-14",2,{"510k":56,"classification":57,"enforcement":58,"event":59,"event_backfill":60,"pma":61,"warning_letter":62},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]